Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.

Monitoring the exposure of a drug and its metabolites in humans and preclinical species during drug development is required to ensure that the safety of drug-related components in humans are adequately assessed in the standard toxicology studies. Recently published FDA guidance on metabolites in safety testing (MIST) has generated broad discussion from various perspectives. Most of the opinions and experiences shared among the scientific community are scientifically sound and practical. There are various approaches to assess the metabolite exposure margin between toxicology species and humans: either by direct or indirect comparison or by qualitative or quantitative comparison. The choice of when and how to pursuit metabolite assessment is based on the overall development strategy of the compound. Therefore, it is important to understand the utility and limitations of analytical instruments in order to apply an appropriate analytical tool to address specific questions posed at different stages of drug development. The urgency of metabolite monitoring depends on the intrinsic nature of the compound, therapeutic intent and objective of the clinical development. The strategy for assessing metabolite exposure in humans should be a holistic approach considering clinical situations and cumulative knowledge of the metabolism of the drug in order to appropriately address metabolite safety in humans. A one-size-fits-all approach is rarely the best use of resources.

[1]  Philip Timmerman,et al.  Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. , 2009, Chemical research in toxicology.

[2]  Thomayant Prueksaritanont,et al.  Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. , 2006, Toxicology and applied pharmacology.

[3]  Mark Wrona,et al.  MSE with mass defect filtering for in vitro and in vivo metabolite identification. , 2007, Rapid communications in mass spectrometry : RCM.

[4]  Yanou Yang,et al.  An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. , 2008, Journal of mass spectrometry : JMS.

[5]  Nirmala Raghavan,et al.  LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. , 2007, Drug metabolism letters.

[6]  R. Subramanian,et al.  Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. , 2006, Journal of mass spectrometry : JMS.

[7]  Chungping Yu,et al.  A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. , 2007, Rapid communications in mass spectrometry : RCM.

[8]  Ragu Ramanathan,et al.  Response normalized liquid chromatography nanospray ionization mass spectrometry , 2007, Journal of the American Society for Mass Spectrometry.

[9]  W. Humphreys,et al.  Comparative Metabolism of Radiolabeled Muraglitazar in Animals and Humans by Quantitative and Qualitative Metabolite Profiling , 2007, Drug Metabolism and Disposition.

[10]  Sean Yu,et al.  Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. , 2008, Rapid communications in mass spectrometry : RCM.

[11]  G. Valaskovic,et al.  Ultra-low flow nanospray for the normalization of conventional liquid chromatography/mass spectrometry through equimolar response: standard-free quantitative estimation of metabolite levels in drug discovery. , 2006, Rapid communications in mass spectrometry : RCM.

[12]  Jon L Ruckle,et al.  Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. , 2008, Journal of pharmaceutical sciences.

[13]  Sean Yu,et al.  High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line' approach for metabolite identification studies. , 2008, Rapid communications in mass spectrometry : RCM.

[14]  Walter A. Korfmacher,et al.  Systematic LC/MS metabolite identification in drug discovery. , 2001, Analytical chemistry.

[15]  A. Crozier,et al.  Detection and identification of 14C-labelled flavonol metabolites by high-performance liquid chromatography-radiocounting and tandem mass spectrometry. , 2003, Journal of chromatography. A.

[16]  S. Singhvi,et al.  Biotransformation of pravastatin sodium in humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Donglu Zhang,et al.  Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. , 2008, Rapid communications in mass spectrometry : RCM.

[18]  Wei Ding,et al.  A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices. , 2009, Rapid communications in mass spectrometry : RCM.

[19]  D. Luffer-Atlas.  Unique/Major Human Metabolites: Why, How, and When to Test for Safety in Animals , 2008 .

[20]  W. Humphreys,et al.  The use of radiolabeled compounds for ADME studies in discovery and exploratory development. , 2004, Current pharmaceutical design.

[21]  W. Humphreys,et al.  Rapid screening and characterization of drug metabolites using a multiple ion monitoring-dependent MS/MS acquisition method on a hybrid triple quadrupole-linear ion trap mass spectrometer. , 2008, Journal of mass spectrometry : JMS.

[22]  W Griffith Humphreys,et al.  Safety assessment of drug metabolites: Characterization of chemically stable metabolites. , 2006, Chemical research in toxicology.

[23]  C. Hop.  Use of nano-electrospray for metabolite identification and quantitative absorption, distribution, metabolism and excretion studies. , 2006, Current drug metabolism.

[24]  Austin C. Li,et al.  'N-in-one' strategy for metabolite identification using a liquid chromatography/hybrid triple quadrupole linear ion trap instrument using multiple dependent product ion scans triggered with full mass scan. , 2007, Rapid communications in mass spectrometry : RCM.

[25]  G. Dear,et al.  Utilizing a -100 degrees C microplate CCD Imager, yttrium silicate coated 384-microplates and ultra-performance liquid chromatography for improved profiling of radiolabeled drug metabolites in complex biological samples. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  K. Pang,et al.  Safety testing of metabolites: Expectations and outcomes. , 2009, Chemico-biological interactions.

[27]  R Scott Obach,et al.  Metabolites and safety: What are the concerns, and how should we address them? , 2006, Chemical research in toxicology.

[28]  W. Humphreys,et al.  Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. , 2007, Chemical research in toxicology.

[29]  J. Vogel.  Accelerator mass spectrometry for quantitative in vivo tracing. , 2005, BioTechniques.

[30]  R. King,et al.  The use of Qtrap technology in drug metabolism. , 2006, Current drug metabolism.

[31]  R Scott Obach,et al.  Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. , 2009, Chemical research in toxicology.

[32]  Mingshe Zhu,et al.  Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. , 2009, Chemico-biological interactions.

[33]  Jie Chen,et al.  Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap. , 2007, Rapid communications in mass spectrometry : RCM.

[34]  B. Warrack,et al.  Utility of the hybrid LTQ-FTMS for drug metabolism applications. , 2006, Current drug metabolism.

[35]  E. Duchoslav,et al.  Rapid screening and characterization of drug metabolites using multiple ion monitoring dependent product ion scan and postacquisition data mining on a hybrid triple quadrupole-linear ion trap mass spectrometer. , 2009, Rapid communications in mass spectrometry : RCM.

[36]  G. Dear,et al.  Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[37]  Donglu Zhang,et al.  A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. , 2003, Journal of mass spectrometry : JMS.

[38]  David Q. Liu,et al.  Use of a quadrupole linear ion trap mass spectrometer in metabolite identification and bioanalysis. , 2003, Rapid communications in mass spectrometry : RCM.

[39]  Scott Peterman,et al.  An integrated method for metabolite detection and identification using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. , 2008, Journal of mass spectrometry : JMS.

[40]  Adedayo Adedoyin,et al.  Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. , 2009, Chemical research in toxicology.

[41]  D. Dalvie,et al.  Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics. , 2000, Current pharmaceutical design.

[42]  S. Bjorge,et al.  On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. , 2003, Analytical chemistry.

[43]  M. Kiffe,et al.  Combination of high-performance liquid chromatography and microplate scintillation counting for crop and animal metabolism studies: a comparison with classical on-line and thin-layer chromatography radioactivity detection. , 2003, Analytical chemistry.

[44]  Disposition and Metabolism of [14C]Brasofensine in Rats, Monkeys, and Humans , 2008, Drug Metabolism and Disposition.

[45]  S. N. Comezoglu,et al.  ADME Studies in Animals and Humans: Experimental Design, Metabolite Profiling and Identification, and Data Presentation , 2007 .

[46]  L. Leuthold,et al.  Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. , 2004, Journal of mass spectrometry : JMS.

[47]  Mingshe Zhu,et al.  Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. , 2007, Analytical chemistry.

[48]  Mingshe Zhu,et al.  High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. , 2008, Analytical chemistry.

[49]  T. Baillie.  Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials. , 2009, Chemical research in toxicology.

[50]  Adam H Love,et al.  Quantitating isotopic molecular labels with accelerator mass spectrometry. , 2005, Methods in enzymology.

[51]  Mingshe Zhu,et al.  Chapter 9 Quantification and structural elucidation of low quantities of radiolabeled metabolites using microplate scintillation counting (msc) techniques in conjunction with lc-ms , 2005 .

[52]  F. Vanhaecke,et al.  Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development , 2008, Analytical and bioanalytical chemistry.

[53]  Weiping Zhao,et al.  Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. , 2005, Journal of pharmaceutical and biomedical analysis.

[54]  J. Castro-Pérez.  Current and future trends in the application of HPLC-MS to metabolite-identification studies. , 2007, Drug discovery today.

[55]  G. Dear,et al.  TopCount coupled to ultra-performance liquid chromatography for the profiling of radiolabeled drug metabolites in complex biological samples. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[56]  Jennifer H Granger,et al.  Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-flight mass spectrometer. , 2005, Rapid communications in mass spectrometry : RCM.

[57]  T. Baillie,et al.  Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.

[58]  R Scott Obach,et al.  SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING , 2005, Drug Metabolism and Disposition.

[59]  Jie Chen,et al.  A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.

[60]  W. Humphreys,et al.  Applications of Liquid Radiochromatography Techniques in Drug Metabolism Studies , 2007 .

[61]  Jianyao Wang,et al.  Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. , 2009, Chemical research in toxicology.

[62]  L. Leclercq,et al.  Improved liquid chromatography-Online radioactivity detection for metabolite profiling. , 2008, Journal of chromatography. A.

[63]  W. Humphreys,et al.  Metabolite Generation via Microbial Biotransformations with Actinomycetes: Rapid Screening for Active Strains and Biosynthesis of Important Human Metabolites of Two Development-Stage Compounds, 5-[(5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methy , 2008, Drug Metabolism and Disposition.

[64]  Steven R Tannenbaum,et al.  Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. , 2007, Drug metabolism letters.

[65]  P. Zhao,et al.  A SIMPLE SEQUENTIAL INCUBATION METHOD FOR DECONVOLUTING THE COMPLICATED SEQUENTIAL METABOLISM OF CAPRAVIRINE IN HUMANS , 2005, Drug Metabolism and Disposition.

[66]  Donglu Zhang,et al.  Detection and Characterization of Metabolites in Biological Matrices Using Mass Defect Filtering of Liquid Chromatography/High Resolution Mass Spectrometry Data , 2006, Drug Metabolism and Disposition.

[67]  A. Nassar,et al.  Novel approach to performing metabolite identification in drug metabolism. , 2007, Journal of chromatographic science.

[68]  Mingshe Zhu,et al.  An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. , 2008, Journal of mass spectrometry : JMS.